KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacific Biosciences Of California (PACB) EPS (Weighted Average and Diluted) (2016 - 2025)

Pacific Biosciences Of California (PACB) has 8 years of EPS (Weighted Average and Diluted) data on record, last reported at -$0.12 in Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 72.73% year-over-year to -$0.12; the TTM value through Dec 2025 reached -$1.82, down 14.47%, while the annual FY2025 figure was -$1.82, 14.47% down from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.12 in Q4 2025 per PACB's latest filing, up from -$0.13 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.08 in Q3 2021 and bottomed at -$1.44 in Q1 2025.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.35, with a median of -$0.31 recorded in 2023.
  • The widest YoY moves for EPS (Weighted Average and Diluted): up 157.14% in 2021, down 4600.0% in 2021.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.33 in 2021, then dropped by 12.12% to -$0.37 in 2022, then grew by 16.22% to -$0.31 in 2023, then crashed by 41.94% to -$0.44 in 2024, then skyrocketed by 72.73% to -$0.12 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were -$0.12 in Q4 2025, -$0.13 in Q3 2025, and -$0.13 in Q2 2025.